BGI Genomics (SHE:300676) announced a change in the medical device registration of its hereditary deafness gene detection kit.
The changes expanded the use of the kit from auxiliary deafness diagnosis to include serving as a supplement to conventional physical hearing screening, especially to find drug-induced and late-onset deafness gene carriers that are undetectable via conventional physical hearing screening, according to a Thursday filing with the Shenzhen bourse.
Price (RMB): ¥34.68, Change: ¥-0.10, Percent Change: -0.29%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments